Answer from: Medical Oncologist at Academic Institution
While gefitinib + chemo did show a similar PFS as frontline osimertinib, the tolerability and safety profile concerns me. Therefore, I do not plan to change my practice and will still use osimertinib as frontline therapy for my patients with EGFR mutated stage IV lung cancer.
Answer from: Medical Oncologist at Academic Institution
The trial comparing gefitinib to gefitinib and carboplatin + pemetrexed in advanced, treatment naïve EGFR mutated NSCLC presented by Dr. Noronha at ASCO 2019 was performed in a setting where osimertinib is not always accessible for patients. The PFS is clearly better with the combination than with...
Answer from: Medical Oncologist at Academic Institution
There are now 2 trials (one from Japan and one from India) that report the addition of carboplatin plus pemetrexed to gefitinib improves overall survival compared with gefitinib alone in patients with stage IV EGFR mutated non-small cell lung cancer. For patients who receive their medical care...
Answer from: Medical Oncologist at Academic Institution
No. Gefitinib is no longer the standard of care for first line EGFR mutant disease. Osimertinib has significantly better outcomes and less toxicity than either gefitinib or gefitinib plus chemotherapy, and prevents the emergence of brain metastases.
Answer from: Medical Oncologist at Academic Institution
In the mednet poll most providers voted for Osimertinib as the preferred front line which is currently the standard of care in USA, and it makes sense to continue this practice since it is definitely a better drug and has CNS penetration as the experts indicate above.
Interestingly, a p...
Comments
Medical Oncologist at Sarah Cannon Cancer Institute at Menorah Medical Center In the settings where Osi is not available, the us...
Answer from: Medical Oncologist at Academic Institution
Combining chemo and TKI has been evaluated previously. Even though recent efficacy data is promising, toxicity is of concern. I do not plan on changing my front line TKI option based on this new data